Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sa3
Stanford, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SA3 is an early-stage biotechnology company focused on developing novel therapeutic interventions targeting the STAG3 protein, a key component of the cohesin complex. The company leverages its proprietary platform to identify and optimize small molecule inhibitors and peptide-based therapies designed to disrupt oncogenic signaling in various solid tumors. By targeting the specific vulnerabilities associated with STAG3 overexpression or mutation, SA3 aims to provide precision medicine solutions for patients with limited treatment options. The company's research is grounded in deep expertise in chromosome biology and structural proteomics.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
Beyond the preview
Go deeper on Sa3.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sa3.